SUPN — Supernus Pharmaceuticals, Inc.

Summary of Supernus Pharmaceuticals, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $207.7 million, a 39% increase year-over-year.
• Commercial Product Revenue: $178 million, up 26% from the previous year.
• Adjusted Operating Earnings: $28.7 million, compared to $25.9 million in Q1 2025.
• GAAP Net Loss: $2.3 million ($0.04 per share), improved from a net loss of $11.8 million ($0.21 per share) in Q1 2025.
• Cash Position: Approximately $384 million in cash, cash equivalents, and marketable securities, reflecting strong operational cash generation.

2. Strategic Updates and Business Highlights

• Onepco: Generated $8.4 million in net sales with a rebound in patient initiations post-supply constraints. March 2026 metrics exceeded pre-constraint levels.
• Zirzuve: Collaboration revenues of $27.6 million, with U.S. sales of XERZUVEY doubling year-over-year.
• KELLI: Prescriptions grew by 19%, with net sales reaching $78 million, a 20% increase.
• GOCOVRI: Net sales of $35.2 million, up 15% year-over-year.
• R&D Initiatives: Ongoing trials for SPN-820 and SPN-817, with plans to initiate a Phase 1 study for SPN-443.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Reiterated total revenue expectations between $840 million and $870 million.
• Combined R&D and SG&A Expenses: Expected to range from $620 million to $650 million.
• Operating Earnings: Forecasted between $0 million and $30 million, with non-GAAP operating earnings projected between $140 million and $170 million.

4. Bad News, Challenges, or Points of Concern

• Operating Loss: Despite improved revenues, the company reported an operating loss, indicating ongoing cost pressures, particularly in SG&A expenses related to collaborations.
• Patient Conversion Rates: Concerns regarding the conversion of start forms to paying patients for Onepco, with an estimated 40-45% dropout rate during the process.
• Supply Chain Risks: Ongoing supply constraints and the need for a second supplier for Onepco, with potential regulatory hurdles.
• Market Competition: Competitive dynamics between Onepco and other treatments like Vylev, with physicians assessing patient profiles and treatment efficacy.

5. Notable Q&A Insights

• Patient Conversion for Onepco: Management indicated that approximately 570 patients are currently in the queue, with expectations for improved processing and conversion rates as operations stabilize.
• XERZUVEY Growth: Strong prescription growth and broadening prescriber base, with ongoing direct-to-consumer (DTC) campaigns aimed at increasing awareness and education.
• M&A Strategy: Focus remains on acquiring revenue-generating assets or late-stage products, with a preference for wholly-owned opportunities.
• FDA Interactions: Management expressed confidence in meeting timelines for regulatory submissions and approvals for Onepco, based on ongoing discussions with the FDA.

Overall, Supernus Pharmaceuticals demonstrated strong financial performance in Q1 2026, with significant growth in key products and a solid cash position, while navigating challenges related to patient conversion rates and supply chain management.